← brief for 2026-08-31 · Slowing decline

Anti-LCN2 antibody treatment is associated with attenuated hearing loss and blood–labyrinth barrier disruption in a mouse model of chronic kidney disease

Paper D Peer reviewed Preclinical

Key takeaways

In mice with kidney disease, an experimental antibody reduced hearing loss and protected a barrier in the inner ear. The study was done in animals only — no people were tested yet.

Who did this work

Ding Ye (Hangzhou Medical College) · Jiang Xin (Zhejiang University) · Xiangming Ye (Hangzhou Medical College)

Source

Paper · OpenAlex, CKD works · 2026-08-30
https://doi.org/10.1007/s10735-026-10963-4